These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20628715)

  • 1. [Therapy of obesity with liraglutide. NN8022-1807 study].
    Scherbaum WA; Nitschmann S
    Internist (Berl); 2010 Aug; 51(8):1064-6. PubMed ID: 20628715
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
    Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
    Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal hormones and weight management.
    Bray GA
    Lancet; 2009 Nov; 374(9701):1570-1. PubMed ID: 19853907
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
    Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
    Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacotherapy for weight loss in patients with type 2 diabetes].
    Toubro S
    Ugeskr Laeger; 2007 Aug; 169(33):2619-22. PubMed ID: 17725907
    [No Abstract]   [Full Text] [Related]  

  • 7. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
    Elkhenini H; New JP; Summers LK; Syed AA
    Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 10. Liraglutide for weight loss in obese people.
    Hallberg P; Schwan S; Melhus H
    Lancet; 2010 Feb; 375(9714):551; author reply 552-3. PubMed ID: 20159284
    [No Abstract]   [Full Text] [Related]  

  • 11. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
    Pi-Sunyer X; Astrup A; Fujioka K; Greenway F; Halpern A; Krempf M; Lau DC; le Roux CW; Violante Ortiz R; Jensen CB; Wilding JP;
    N Engl J Med; 2015 Jul; 373(1):11-22. PubMed ID: 26132939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advancements in drug treatment of obesity.
    Carter R; Mouralidarane A; Ray S; Soeda J; Oben J
    Clin Med (Lond); 2012 Oct; 12(5):456-60. PubMed ID: 23101148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
    Wadden TA; Hollander P; Klein S; Niswender K; Woo V; Hale PM; Aronne L;
    Int J Obes (Lond); 2013 Nov; 37(11):1443-51. PubMed ID: 23812094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide for weight loss in obese people.
    Thum T; Anker SD
    Lancet; 2010 Feb; 375(9714):551-2; author reply 552-3. PubMed ID: 20159285
    [No Abstract]   [Full Text] [Related]  

  • 19. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance.
    Aronne LJ; Finer N; Hollander PA; England RD; Klioze SS; Chew RD; Fountaine RJ; Powell CM; Obourn JD
    Obesity (Silver Spring); 2011 Jul; 19(7):1404-14. PubMed ID: 21293451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.